The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systemati
- PDF / 3,410,086 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 9 Downloads / 189 Views
RESEARCH ARTICLE
The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non‑small‑cell lung cancer: a systematic review and meta‑analysis Y. Yang1 · H. Luo1 · X. L. Zheng1 · H. Ge1 Received: 11 May 2020 / Accepted: 15 September 2020 © Federación de Sociedades Españolas de Oncología (FESEO) 2020
Abstract Background Immune checkpoint inhibitors (ICIs) plus chemotherapy (CT) have strikingly expanded the therapeutic landscape for advanced non-small cell lung cancer (NSCLC), but little is known about which is superior. We performed a metaanalysis that compared the efficacy and safety of PD-1 inhibitor + CT with PD-L1 inhibitor + CT. Methods PubMed, Embase, Web of Science, Cochrane Library, and major international scientific meetings were searched for relevant randomized controlled trials (RCTs), and the indirect analysis was performed for PD-1 + CT vs PD-L1 + CT. The outcomes included progression-free survival (PFS), overall survival (OS), objective response rate (ORR) and treatmentrelated adverse events (TRAEs). Results 8 phase III RCTs with 4253 patients comparing PD-1/PD-L1 + CT in NSCLC were included. The PD-1 + CT led to notably longer OS most in low/negative expression of PD-L1 for NSCLC patients compared with PD-L1 + CT. In terms of Grade 3–5 TRAEs, the results showed that PD-1 + CT and PD-L1 + CT exclusively increased the risk of adverse incidence than CT alone, especially for PD-L1 + CT (p
Data Loading...
